Gargoyle Investment Advisor Has Decreased Anthem (ANTM) Position By $756,000; GW Pharmaceuticals plc (GWPH) Had 11 Bullish Analysts

February 19, 2018 - By Stephen Andrade

Gargoyle Investment Advisor Llc decreased Anthem Inc (ANTM) stake by 22.22% reported in 2017Q3 SEC filing. Gargoyle Investment Advisor Llc sold 4,000 shares as Anthem Inc (ANTM)’s stock rose 10.08%. The Gargoyle Investment Advisor Llc holds 14,000 shares with $2.66M value, down from 18,000 last quarter. Anthem Inc now has $60.34B valuation. The stock increased 1.28% or $2.96 during the last trading session, reaching $235.02. About 1.09M shares traded. Anthem, Inc. (NYSE:ANTM) has risen 31.86% since February 19, 2017 and is uptrending. It has outperformed by 15.16% the S&P500.

Among 13 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. GW Pharmaceuticals had 28 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, December 5. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Buy” rating given on Monday, August 7 by Maxim Group. Maxim Group maintained the shares of GWPH in report on Thursday, June 8 with “Buy” rating. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) earned “Buy” rating by Cantor Fitzgerald on Tuesday, August 8. The company was maintained on Thursday, October 26 by Cowen & Co. The rating was upgraded by Numis Securities on Friday, August 26 to “Hold”. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Outperform” rating given on Monday, October 2 by Leerink Swann. The company was initiated on Friday, October 7 by Goldman Sachs. Roth Capital maintained it with “Buy” rating and $160 target in Monday, March 14 report. The firm has “Overweight” rating by Morgan Stanley given on Thursday, August 13. See GW Pharmaceuticals plc (NASDAQ:GWPH) latest ratings:

06/02/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $154 New Target: $149 Maintain
06/02/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $153 New Target: $157 Maintain
05/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $192.0 Maintain
23/01/2018 Broker: Leerink Swann Rating: Buy New Target: $153.0 Maintain
28/12/2017 Broker: Leerink Swann Rating: Buy Maintain
14/12/2017 Broker: Goldman Sachs Rating: Buy New Target: $174.0 Upgrade
04/12/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $208.0 Maintain
14/11/2017 Broker: Bank of America Rating: Buy Old Target: $160 New Target: $158 Maintain
26/10/2017 Broker: Cowen & Co Rating: Buy New Target: $165.0 Maintain
02/10/2017 Broker: Leerink Swann Rating: Outperform Old Target: $160 New Target: $153 Maintain

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company has market cap of $3.64 billion. It operates through three divisions: Commercial, Sativex Research and Development, and Pipeline Research and Development. It currently has negative earnings. The firm markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis.

The stock increased 0.26% or $0.34 during the last trading session, reaching $131.01. About 205,098 shares traded. GW Pharmaceuticals plc (NASDAQ:GWPH) has risen 31.90% since February 19, 2017 and is uptrending. It has outperformed by 15.20% the S&P500.

Among 24 analysts covering Anthem Inc (NYSE:ANTM), 15 have Buy rating, 0 Sell and 9 Hold. Therefore 63% are positive. Anthem Inc had 73 analyst reports since July 27, 2015 according to SRatingsIntel. On Friday, January 8 the stock rating was maintained by Jefferies with “Buy”. Cantor Fitzgerald maintained the shares of ANTM in report on Wednesday, July 26 with “Buy” rating. Jefferies maintained the shares of ANTM in report on Friday, October 13 with “Hold” rating. The stock of Anthem, Inc. (NYSE:ANTM) has “Buy” rating given on Thursday, September 14 by Cantor Fitzgerald. Cantor Fitzgerald upgraded the stock to “Overweight” rating in Friday, April 28 report. The rating was upgraded by Goldman Sachs to “Buy” on Wednesday, January 20. The firm has “Buy” rating given on Thursday, July 27 by RBC Capital Markets. On Wednesday, October 25 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm has “Hold” rating given on Wednesday, June 7 by Jefferies. The firm has “Mkt Perform” rating by FBR Capital given on Thursday, October 29.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: